Increased vimentin in human α- and β-cells in type 2 diabetes
(2017) In Journal of Endocrinology 233(3). p.217-227- Abstract
Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with T2DM (n = 28) and without diabetes (ND, n = 38) and in non-human... (More)
Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with T2DM (n = 28) and without diabetes (ND, n = 38) and in non-human primates at different stages of the diabetic syndrome: normoglycaemic (ND, n = 4), obese, hyperinsulinaemic (HI, n = 4) and hyperglycaemic (DM, n = 8). Vimentin co-localised more frequently with glucagon (α-cells) than with insulin (β-cells) in the human ND group (1.43% total α-cells, 0.98% total β-cells, median; P < 0.05); these proportions were higher in T2DM than ND (median 4.53% α-, 2.53% β-cells; P < 0.05). Vimentin-positive β-cells were not apoptotic, had reduced expression of Nkx6.1 and Pdx1, and were not associated with islet amyloidosis or with bihormonal expression (insulin + glucagon). In non-human primates, vimentin-positive β-cell proportion was larger in the diabetic than the ND group (6.85 vs 0.50%, medians respectively, P < 0.05), but was similar in ND and HI groups. In conclusion, islet cell expression of vimentin indicates a degree of plasticity and dedifferentiation with potential loss of cellular identity in diabetes. This could contribute to α- and β-cell dysfunction in T2DM.
(Less)
- author
- publishing date
- 2017-06
- type
- Contribution to journal
- publication status
- published
- subject
- keywords
- Animals, Case-Control Studies, Cells, Cultured, Diabetes Mellitus, Type 2/metabolism, Glucagon-Secreting Cells/metabolism, Humans, Hyperinsulinism/metabolism, Insulin-Secreting Cells/metabolism, Macaca fascicularis, Macaca mulatta, Vimentin/metabolism
- in
- Journal of Endocrinology
- volume
- 233
- issue
- 3
- pages
- 11 pages
- publisher
- Society for Endocrinology
- external identifiers
-
- pmid:28348116
- scopus:85019993664
- ISSN
- 1479-6805
- DOI
- 10.1530/JOE-16-0588
- language
- English
- LU publication?
- no
- additional info
- © 2017 Society for Endocrinology.
- id
- 1731b7c1-fb55-4b61-a789-882c6e1fdf75
- date added to LUP
- 2019-05-22 16:58:33
- date last changed
- 2024-02-15 08:57:46
@article{1731b7c1-fb55-4b61-a789-882c6e1fdf75,
abstract = {{<p>Type 2 diabetes (T2DM) is associated with pancreatic islet dysfunction. Loss of β-cell identity has been implicated via dedifferentiation or conversion to other pancreatic endocrine cell types. How these transitions contribute to the onset and progression of T2DM in vivo is unknown. The aims of this study were to determine the degree of epithelial-to-mesenchymal transition occurring in α and β cells in vivo and to relate this to diabetes-associated (patho)physiological conditions. The proportion of islet cells expressing the mesenchymal marker vimentin was determined by immunohistochemistry and quantitative morphometry in specimens of pancreas from human donors with T2DM (n = 28) and without diabetes (ND, n = 38) and in non-human primates at different stages of the diabetic syndrome: normoglycaemic (ND, n = 4), obese, hyperinsulinaemic (HI, n = 4) and hyperglycaemic (DM, n = 8). Vimentin co-localised more frequently with glucagon (α-cells) than with insulin (β-cells) in the human ND group (1.43% total α-cells, 0.98% total β-cells, median; P < 0.05); these proportions were higher in T2DM than ND (median 4.53% α-, 2.53% β-cells; P < 0.05). Vimentin-positive β-cells were not apoptotic, had reduced expression of Nkx6.1 and Pdx1, and were not associated with islet amyloidosis or with bihormonal expression (insulin + glucagon). In non-human primates, vimentin-positive β-cell proportion was larger in the diabetic than the ND group (6.85 vs 0.50%, medians respectively, P < 0.05), but was similar in ND and HI groups. In conclusion, islet cell expression of vimentin indicates a degree of plasticity and dedifferentiation with potential loss of cellular identity in diabetes. This could contribute to α- and β-cell dysfunction in T2DM.</p>}},
author = {{Roefs, Maaike M and Carlotti, Françoise and Jones, Katherine and Wills, Hannah and Hamilton, Alexander and Verschoor, Michael and Durkin, Joanna M Williams and Garcia-Perez, Laura and Brereton, Melissa F and McCulloch, Laura and Engelse, Marten A and Johnson, Paul R V and Hansen, Barbara C and Docherty, Kevin and de Koning, Eelco J P and Clark, Anne}},
issn = {{1479-6805}},
keywords = {{Animals; Case-Control Studies; Cells, Cultured; Diabetes Mellitus, Type 2/metabolism; Glucagon-Secreting Cells/metabolism; Humans; Hyperinsulinism/metabolism; Insulin-Secreting Cells/metabolism; Macaca fascicularis; Macaca mulatta; Vimentin/metabolism}},
language = {{eng}},
number = {{3}},
pages = {{217--227}},
publisher = {{Society for Endocrinology}},
series = {{Journal of Endocrinology}},
title = {{Increased vimentin in human α- and β-cells in type 2 diabetes}},
url = {{http://dx.doi.org/10.1530/JOE-16-0588}},
doi = {{10.1530/JOE-16-0588}},
volume = {{233}},
year = {{2017}},
}